TCGA-CR-7365-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.480
- TGF_BETA_SIGNALING+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- MITOTIC_SPINDLE+0.410
- APICAL_JUNCTION+0.380
- ANGIOGENESIS+0.350
- ESTROGEN_RESPONSE_EARLY+0.350
- UV_RESPONSE_DN+0.320
- HYPOXIA+0.300
- HEDGEHOG_SIGNALING+0.280
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- ALLOGRAFT_REJECTION-0.290
- FATTY_ACID_METABOLISM-0.220
- INTERFERON_ALPHA_RESPONSE-0.180
- INTERFERON_GAMMA_RESPONSE-0.150
- PANCREAS_BETA_CELLS-0.130
- ADIPOGENESIS-0.110
- DNA_REPAIR-0.100
- SPERMATOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8145-01A-11R-2247-07 | — | cohortSQ1 | 0.797 |
| 2 | TCGA-73-4668-01A-01R-1206-07 | — | cohortA1 | 0.775 |
| 3 | TCGA-BH-A201-01A-11R-A14M-07 | — | A | 0.771 |
| 4 | TCGA-85-A50M-01A-21R-A262-07 | — | cohortSQ1 | 0.771 |
| 5 | SRR9879274 | — | cohortSQ1 | 0.762 |
| 6 | TCGA-CN-5355-01A-01R-1436-07 | — | — | 0.758 |
| 7 | TCGA-85-8582-01A-21R-2403-07 | — | cohortSQ1 | 0.757 |
| 8 | TCGA-CV-6950-01A-11R-1915-07 | — | — | 0.756 |
| 9 | MNG984 | — | — | 0.743 |
| 10 | TCGA-85-8353-01A-21R-2296-07 | — | cohortSQ1 | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.480 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |